Back

Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy

27 August 2022 (08:15 - 09:00)
Organised by:
Congress Presentation Part of: Chronic heart failure - Amyloidosis Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Ronald Witteles

Stanford University, Stanford (United States of America)

6 More presentations in this session

Presentation thumbnail
Diagnostic accuracy of amyloid scintigraphy for the histopathological diagnosis of cardiac transthyretin amyloidosis - a retrospective Austrian multicenter study
Doctor N. Verheyen (Graz, AT)
Abstract Slides
Presentation thumbnail
The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis
Assistant Professor A. Briasoulis (Athens, GR)
Abstract Slides
Presentation thumbnail
Hypertension is associated with more advanced heart failure in african americans with suspected cardiac amyloidosis
Doctor S. Manjunath (Saint Louis, US)
Abstract Slides
Presentation thumbnail
Clinical characteristics, patient selection and clinical outcomes of tafamidis treatment in transthyretin amyloidosis cardiomyopathy
Doctor S. Takashio (Kumamoto, JP)
Abstract Slides
Presentation thumbnail
Histological validation of cardiac 99mTc-DPD uptake in patients with cardiac transthyretin amyloidosis
Doctor M. Ungericht (Innsbruck, AT) Associate Professor G. Polzl (Innsbruck, AT)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - Amyloidosis

The Event

Event poster

ESC Congress 2022

27 August 2022 08:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources